智通财经APP讯，九源基因(02566)公布，聚乙二醇化人粒细胞刺激因子注射液(商标名：吉新芬®)已获中华人民共和国国家药品监督管理局批准上市，用于治疗成年非髓性恶性肿瘤患者在接受易引起发热性中性粒细胞减少症的骨髓抑制性抗癌药物治疗时，降低以发热性中性粒细胞减少症为表现的感染发生率。
吉新芬®由人粒细胞刺激因子(hG-CSF)与20KD聚乙二醇交联并经纯化获得，半衰期明显延长，生物稳定性增强，不易被酶解，免疫原性与抗原性降低，不易产生中和性抗体。聚乙二醇化人粒细胞刺激因子(PEG-hG-CSF)一个化疗周期仅需一次给药，提高患者依从性，有效保障患者安全及化疗方案足剂量足疗程实施。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.